Enablex
Enablex Brand names, Enablex Analogs
Enablex Brand Names Mixture
- Cystosol W 3% Hexitols (Mannitol + Sorbitol)
- Sorbitol Mannitol Irrigation (Mannitol + Sorbitol)
Enablex Chemical_Formula
C28H30N2O2
Enablex RX_link
http://www.rxlist.com/cgi/generic3/enablex.htm
Enablex fda sheet
Enablex msds (material safety sheet)
Enablex Synthesis Reference
No information avaliable
Enablex Molecular Weight
426.55 g/mol
Enablex Melting Point
No information avaliable
Enablex H2O Solubility
No information avaliable
Enablex State
Solid
Enablex LogP
4.832
Enablex Dosage Forms
Extended-release tablets (containing 7.5 mg or 15 mg darifenacin as hydrobromide salt)
Enablex Indication
For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
Enablex Pharmacology
Darifenacin is a competitive muscarinic receptor antagonist. In vitro studies using human recombinant muscarinic receptor subtypes show that darifenacin has greater affinity for the M3 receptor than for the other known muscarinic receptors (9 and 12-fold greater affinity for M3 compared to M1 and M5, respectively, and 59-fold greater affinity for M3 compared to both M2 and M4). Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of the urinary bladder smooth muscle and stimulation of salivary secretion. Adverse drug effects such as dry mouth, constipation and abnormal vision may be mediated through effects on M3 receptors in these organs.
Enablex Absorption
The mean oral bioavailability at steady state is estimated to be 15% and 19% for 7.5 mg and 15 mg tablets, respectively.
Enablex side effects and Toxicity
Overdosage can potentially result in severe central anticholinergic effects.
Enablex Patient Information
Enablex Organisms Affected
Humans and other mammals
